In a shocking move, pharmaceutical giant Novo Nordisk has taken to the courts to take on rival Eli Lilly, accusing the company of engaging in deceptive marketing practices. A lawsuit filed in federal district court in New Jersey alleges that Lilly has been misleading consumers about the effectiveness of its weight loss medications, Mounjaro and Zepbound, by cherry-picking outdated studies to create a false narrative that they outperform Novo Nordisk's competing product, Ozempic. The lawsuit claims that Lilly's actions are not only a threat to consumers but also to the integrity of the pharmaceutical industry as a whole. As the weight loss medication market continues to grow, the stakes are high, and this lawsuit is likely to have far-reaching implications for both companies and the millions of people who rely on these medications for their health.
Drugmaker Novo Nordisk sued rival Eli Lilly on Tuesday, accusing the company of false advertising over the performance of its weight loss drugs. The lawsuit, filed in federal district court in New Jersey, alleges Lilly intentionally selected outdated studies to show the use of Mounjaro and Zepbound lead to significantly more weight loss than Novo Nordisk’s Ozempic and...
